ArticleEndocrine connections2026
Metformin improves endotoxemia and alters folliculogenesis in women with polycystic ovary syndrome.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is associated with excessive ovarian androgen production, increased number of ovarian follicles and a wide range of other endocrine and metabolic derangements including endotoxemia. Metformin is often used in treatment of PCOS, especially to improve glucose metabolism. This study evaluated effects of metformin on endotoxemia, folliculogenesis and endocrine profiles. In a prospective trial, women with PCOS received metformin (500 mg t.i.d.) for three months and underwent baseline and post-treatment evaluations of their endocrine and metabolic profiles as well as detailed ultrasonographic evaluations of ovaries. Metformin treatment was associated with reduced lipopolysaccharides (LPS) by 19% (P<0.0001) and LPS binding protein (LPB) by 26% (P<0.0001). In parallel, the number of small antral follicles (<6mm) declined by 8% (P=0.005), total testosterone decreased by 13% (P=0.0003), ovarian testosterone production in response to hCG declined by 73% (P=0.03) and fasting insulin decreased by 19% (P=0.02). Reduction of testosterone following treatment with metformin may be due to a combination of multiple effects of metformin including improvement of endotoxemia, reduction of folliculogenesis and decreased insulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.